- Home
- PCH vs ACAD Comparison
PCH vs ACAD Comparison
Compare PCH & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCH
- ACAD
- Stock Information
- Founded
- PCH 1903
- ACAD 1993
- Country
- PCH United States
- ACAD United States
- Employees
- PCH N/A
- ACAD N/A
- Industry
- PCH Real Estate Investment Trusts
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- PCH Real Estate
- ACAD Health Care
- Exchange
- PCH Nasdaq
- ACAD Nasdaq
- Market Cap
- PCH 3.0B
- ACAD 2.5B
- IPO Year
- PCH N/A
- ACAD 2004
- Fundamental
- Price
- PCH $38.35
- ACAD $22.95
- Analyst Decision
- PCH Strong Buy
- ACAD Buy
- Analyst Count
- PCH 7
- ACAD 16
- Target Price
- PCH $48.43
- ACAD $27.00
- AVG Volume (30 Days)
- PCH 515.9K
- ACAD 1.6M
- Earning Date
- PCH 07-28-2025
- ACAD 08-05-2025
- Dividend Yield
- PCH 4.64%
- ACAD N/A
- EPS Growth
- PCH 7.03
- ACAD N/A
- EPS
- PCH 0.61
- ACAD 1.37
- Revenue
- PCH $1,102,209,000.00
- ACAD $996,283,000.00
- Revenue This Year
- PCH $2.82
- ACAD $13.39
- Revenue Next Year
- PCH $4.67
- ACAD $10.68
- P/E Ratio
- PCH $63.85
- ACAD $16.75
- Revenue Growth
- PCH 10.86
- ACAD 22.42
- 52 Week Low
- PCH $36.82
- ACAD $13.40
- 52 Week High
- PCH $48.12
- ACAD $25.23
- Technical
- Relative Strength Index (RSI)
- PCH 44.61
- ACAD 69.10
- Support Level
- PCH $38.55
- ACAD $21.35
- Resistance Level
- PCH $40.63
- ACAD $22.69
- Average True Range (ATR)
- PCH 0.92
- ACAD 0.77
- MACD
- PCH -0.07
- ACAD -0.13
- Stochastic Oscillator
- PCH 27.16
- ACAD 80.93
About PCH PotlatchDeltic Corporation
PotlatchDeltic Corp is a REIT that owns and manages forestland in Alabama, Arkansas, Idaho, Minnesota, and Mississippi. Potlach operates in three segments. The timberlands segment covers the planting and harvesting of trees, as well as the construction and maintenance of roads. The wood products segment manufactures and distributes lumber, plywood, and other wood products. The real estate segment covers the sales generated from company-owned timberlands, as well as commercial and residential properties. The timberlands and the wood product segments combined drive the majority of the company's revenue.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.